Methotrexate and misoprostol for early abortion: A multicenter trial. I. Safety and efficacy

Mitchell D Creinin, Eric Vittinghoff, Lisa Keder, Philip D. Darney, George Tiller

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

A prospective trial was conducted including 300 pregnant women seeking elective abortion to evaluate the safety and efficacy of methotrexate and misoprostol for abortion at ≤56 days gestation. Subjects received methotrexate 50 mg/m2 intramuscularly followed 7 days later by misoprostol 800 μg vaginally. The misoprostol dose was repeated the next day if the abortion did not occur. Outcome measures included successful abortion (complete abortion without requiring a surgical procedure), duration of vaginal bleeding, and side effects. Complete abortion occurred in 263/300 (87.7%, 95% CI 83.4, 91.2%) patients. The complete abortion rate was higher for early gestations: 183/202 (90.6%, 95% CI 85.7, 94.2%) at ≤49 days gestation, and 80/98 (81.6%, 95% CI 72.5, 88.7%) from 50-56 days gestation (p=0.038). Abortion occurred in the 24 hours following the initial or repeat misoprostol dose (immediate success) in 65.0%; the remaining 22.7% of women who aborted did so after a delay of 23.6 ± 9.1 (mean ± standard deviation) days. Vaginal bleeding lasted 14 ± 7 days and 11 ± 9 days in immediate success and delayed success patients, respectively. Overall, 69.7%, 87.7%, and 91.7% of patients had passed the pregnancy by 14, 28, and 35 days, respectively, after receiving methotrexate. Methotrexate and misoprostol side effects were minimal. This treatment regimen offers an alternative to surgical abortion or the use of antiprogestins and prostaglandin for medical abortion.

Original languageEnglish (US)
Pages (from-to)321-327
Number of pages7
JournalContraception
Volume53
Issue number6
DOIs
StatePublished - Jun 1996
Externally publishedYes

Fingerprint

Misoprostol
Methotrexate
Multicenter Studies
Safety
Pregnancy
Uterine Hemorrhage
Induced Abortion
Prostaglandins
Pregnant Women
Outcome Assessment (Health Care)

Keywords

  • abortion
  • methotrexate
  • misoprostol
  • prostaglandin

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Methotrexate and misoprostol for early abortion : A multicenter trial. I. Safety and efficacy. / Creinin, Mitchell D; Vittinghoff, Eric; Keder, Lisa; Darney, Philip D.; Tiller, George.

In: Contraception, Vol. 53, No. 6, 06.1996, p. 321-327.

Research output: Contribution to journalArticle

Creinin, Mitchell D ; Vittinghoff, Eric ; Keder, Lisa ; Darney, Philip D. ; Tiller, George. / Methotrexate and misoprostol for early abortion : A multicenter trial. I. Safety and efficacy. In: Contraception. 1996 ; Vol. 53, No. 6. pp. 321-327.
@article{d94fdb99d7a340fca8ad78d66a7f6402,
title = "Methotrexate and misoprostol for early abortion: A multicenter trial. I. Safety and efficacy",
abstract = "A prospective trial was conducted including 300 pregnant women seeking elective abortion to evaluate the safety and efficacy of methotrexate and misoprostol for abortion at ≤56 days gestation. Subjects received methotrexate 50 mg/m2 intramuscularly followed 7 days later by misoprostol 800 μg vaginally. The misoprostol dose was repeated the next day if the abortion did not occur. Outcome measures included successful abortion (complete abortion without requiring a surgical procedure), duration of vaginal bleeding, and side effects. Complete abortion occurred in 263/300 (87.7{\%}, 95{\%} CI 83.4, 91.2{\%}) patients. The complete abortion rate was higher for early gestations: 183/202 (90.6{\%}, 95{\%} CI 85.7, 94.2{\%}) at ≤49 days gestation, and 80/98 (81.6{\%}, 95{\%} CI 72.5, 88.7{\%}) from 50-56 days gestation (p=0.038). Abortion occurred in the 24 hours following the initial or repeat misoprostol dose (immediate success) in 65.0{\%}; the remaining 22.7{\%} of women who aborted did so after a delay of 23.6 ± 9.1 (mean ± standard deviation) days. Vaginal bleeding lasted 14 ± 7 days and 11 ± 9 days in immediate success and delayed success patients, respectively. Overall, 69.7{\%}, 87.7{\%}, and 91.7{\%} of patients had passed the pregnancy by 14, 28, and 35 days, respectively, after receiving methotrexate. Methotrexate and misoprostol side effects were minimal. This treatment regimen offers an alternative to surgical abortion or the use of antiprogestins and prostaglandin for medical abortion.",
keywords = "abortion, methotrexate, misoprostol, prostaglandin",
author = "Creinin, {Mitchell D} and Eric Vittinghoff and Lisa Keder and Darney, {Philip D.} and George Tiller",
year = "1996",
month = "6",
doi = "10.1016/0010-7824(96)00080-7",
language = "English (US)",
volume = "53",
pages = "321--327",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Methotrexate and misoprostol for early abortion

T2 - A multicenter trial. I. Safety and efficacy

AU - Creinin, Mitchell D

AU - Vittinghoff, Eric

AU - Keder, Lisa

AU - Darney, Philip D.

AU - Tiller, George

PY - 1996/6

Y1 - 1996/6

N2 - A prospective trial was conducted including 300 pregnant women seeking elective abortion to evaluate the safety and efficacy of methotrexate and misoprostol for abortion at ≤56 days gestation. Subjects received methotrexate 50 mg/m2 intramuscularly followed 7 days later by misoprostol 800 μg vaginally. The misoprostol dose was repeated the next day if the abortion did not occur. Outcome measures included successful abortion (complete abortion without requiring a surgical procedure), duration of vaginal bleeding, and side effects. Complete abortion occurred in 263/300 (87.7%, 95% CI 83.4, 91.2%) patients. The complete abortion rate was higher for early gestations: 183/202 (90.6%, 95% CI 85.7, 94.2%) at ≤49 days gestation, and 80/98 (81.6%, 95% CI 72.5, 88.7%) from 50-56 days gestation (p=0.038). Abortion occurred in the 24 hours following the initial or repeat misoprostol dose (immediate success) in 65.0%; the remaining 22.7% of women who aborted did so after a delay of 23.6 ± 9.1 (mean ± standard deviation) days. Vaginal bleeding lasted 14 ± 7 days and 11 ± 9 days in immediate success and delayed success patients, respectively. Overall, 69.7%, 87.7%, and 91.7% of patients had passed the pregnancy by 14, 28, and 35 days, respectively, after receiving methotrexate. Methotrexate and misoprostol side effects were minimal. This treatment regimen offers an alternative to surgical abortion or the use of antiprogestins and prostaglandin for medical abortion.

AB - A prospective trial was conducted including 300 pregnant women seeking elective abortion to evaluate the safety and efficacy of methotrexate and misoprostol for abortion at ≤56 days gestation. Subjects received methotrexate 50 mg/m2 intramuscularly followed 7 days later by misoprostol 800 μg vaginally. The misoprostol dose was repeated the next day if the abortion did not occur. Outcome measures included successful abortion (complete abortion without requiring a surgical procedure), duration of vaginal bleeding, and side effects. Complete abortion occurred in 263/300 (87.7%, 95% CI 83.4, 91.2%) patients. The complete abortion rate was higher for early gestations: 183/202 (90.6%, 95% CI 85.7, 94.2%) at ≤49 days gestation, and 80/98 (81.6%, 95% CI 72.5, 88.7%) from 50-56 days gestation (p=0.038). Abortion occurred in the 24 hours following the initial or repeat misoprostol dose (immediate success) in 65.0%; the remaining 22.7% of women who aborted did so after a delay of 23.6 ± 9.1 (mean ± standard deviation) days. Vaginal bleeding lasted 14 ± 7 days and 11 ± 9 days in immediate success and delayed success patients, respectively. Overall, 69.7%, 87.7%, and 91.7% of patients had passed the pregnancy by 14, 28, and 35 days, respectively, after receiving methotrexate. Methotrexate and misoprostol side effects were minimal. This treatment regimen offers an alternative to surgical abortion or the use of antiprogestins and prostaglandin for medical abortion.

KW - abortion

KW - methotrexate

KW - misoprostol

KW - prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=0030028245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030028245&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(96)00080-7

DO - 10.1016/0010-7824(96)00080-7

M3 - Article

C2 - 8773418

AN - SCOPUS:0030028245

VL - 53

SP - 321

EP - 327

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6

ER -